Stockreport

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights [Yahoo! Finance]

AN2 Therapeutics, Inc.  (ANTX) 
US:NYSE Investor Relations: ir.antheminc.com
PDF Advancing Phase 2 investigator-initiated trial of epetraborole in M. abscessus complex lung disease; Enrollment expected to begin in 1Q26 with topline results anticipat [Read more]